PARIS--(BUSINESS WIRE)--LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery ...
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from ...
PARIS & SAN JOSE, Calif.--(BUSINESS WIRE)--LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of ...
Inari Medical has agreed to acquire LimFlow, maker of a device to treat patients with chronic limb-threatening loss of blood flow, for $250 million in cash plus potential milestone payments, bringing ...
Inari Medical is betting big on LimFlow, a private company that recently won FDA approval for its transcatheter arterialization of the deep veins (TADV) technology. The LimFlow System is designed to ...
MIAMI, Nov. 7, 2024 /PRNewswire/ -- Pedro Martinez-Clark, MD, FACC, a renowned Harvard-trained cardiologist and founder of Amavita Heart and Vascular™, has joined forces with LimFlow® to offer an ...
PARIS & SAN JOSE, Calif.--(BUSINESS WIRE)-- LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of ...
The LimFlow system employs a covered stent that shunts oxygenated blood around a blocked artery by directing it into a nearby vein. (LimFlow) Inari Medical has signed on to a $415 million deal to ...
PARIS–(BUSINESS WIRE)–#CLI—LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral ...
New Therapeutic Option Has Potential to Reduce Rate of Major Limb Amputation in U.S. LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results